Patent Office Opposes Ruling On Ovarian Cancer Drug, Wants Stronger Obviousness Standard
Executive Summary
After Federal Circuit vacates district court ruling that patent on method of dosing ImmunoGen’s mirvetuximab soravtansine is indefinite and obvious, PTO warns of ‘well-documented problem’ of drug manufacturers receiving follow-on patents for ‘trivial modifications’ that delay generics.